The Oropharyngeal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Oropharyngeal Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued products.

GlobalData tracks 127 drugs in development for Oropharyngeal Cancer by 92 companies/universities/institutes. The top development phase for Oropharyngeal Cancer is phase ii with 74 drugs in that stage. The Oropharyngeal Cancer pipeline has 125 drugs in development by companies and two by universities/ institutes. Some of the companies in the Oropharyngeal Cancer pipeline products market are: AstraZeneca, AbbVie and Merck.

The key targets in the Oropharyngeal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Human Papillomavirus Protein E7 (E7), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).

The key mechanisms of action in the Oropharyngeal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 18 drugs in Phase III. The Oropharyngeal Cancer pipeline products include 18 routes of administration with the top ROA being Intravenous and 18 key molecule types in the Oropharyngeal Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.

Oropharyngeal Cancer overview

Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

For a complete picture of Oropharyngeal Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.